{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:39:20Z","timestamp":1793417960034,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152078","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T11:05:14Z","timestamp":1658919914000},"page":"152078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Predictors of remission in people with axial spondyloarthritis: A systematic literature review"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8357","authenticated-orcid":false,"given":"Ana Sofia","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-1103","authenticated-orcid":false,"given":"Bayram","family":"Farisogullari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2022.152078_bib0001","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152078_bib0003","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/1744666X.2015.1039514","article-title":"Treating to target in axial spondyloarthritis: defining the target and the arrow","volume":"11","author":"Wendling","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/BOR.0000000000000625","article-title":"Treat-to-target in axial spondyloarthritis: gold standard or fools' gold?","volume":"31","author":"Machado","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152078_bib0006","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.berh.2014.10.004","article-title":"Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis","volume":"28","author":"Machado","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152078_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.170222","article-title":"Challenges and advances in targeting remission in axial spondyloarthritis","volume":"45","author":"Baraliakos","year":"2018","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152078_bib0008","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152078_bib0009","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152078_bib0011","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.38921","article-title":"Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort","volume":"67","author":"Machado","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152078_bib0012","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Assessment of spondyloarthritis international S. ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152078_bib0013","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152078_bib0014","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the ankylosing spondylitis disease activity score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152078_bib0016","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3899\/jrheum.131003","article-title":"The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial","volume":"41","author":"van der Heijde","year":"2014","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","article-title":"ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis","volume":"55","author":"van der Heijde","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152078_bib0018","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et\u00a0al. Cochrane Handbook for systematic reviews of interventions version 6.0 (updated July 2019): Cochrane; 2019. Available from: www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152078_bib0019","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0021","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152078_bib0022","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/acr.20131","article-title":"Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics","volume":"62","author":"Maksymowych","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152078_bib0023","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheumatic Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152078_bib0024","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/rheumatology\/kew230","article-title":"Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics","volume":"55","author":"Sieper","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"10142","key":"10.1016\/j.semarthrit.2022.152078_bib0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landewe","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2022.152078_bib0027","series-title":"POS0924 predictors of 1-year treatment response among upadacitinib-treated patients with ankylosing spondylitis: a post hoc analysis of select-AXIS 1","author":"Magrey","year":"2021"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152078_bib0028","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.141278","article-title":"Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials","volume":"42","author":"Baraliakos","year":"2015","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152078_bib0029","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057850","article-title":"Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain","volume":"12","author":"Benavent","year":"2022","journal-title":"BMJ Open"},{"issue":"18","key":"10.1016\/j.semarthrit.2022.152078_bib0031","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.3390\/jcm10184279","article-title":"Early improvements in disease activity indices predict long-term clinical remission suggested by the treat-to-target strategy in patients with ankylosing spondylitis receiving TNF-\u03b1 inhibitor treatment","volume":"10","author":"Nam","year":"2021","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152078_bib0032","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s42358-018-0040-x","article-title":"Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors","volume":"58","author":"Shimabuco","year":"2018","journal-title":"Adv Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152078_bib0034","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","article-title":"Dosage adjustment of anti-tumor necrosis factor-\u03b1 inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice","volume":"39","author":"Paccou","year":"2012","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1849-3","article-title":"Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis","volume":"21","author":"Hern\u00e1ndez-Breijo","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152078_bib0036","article-title":"Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152078_bib0037","doi-asserted-by":"crossref","first-page":"e13013","DOI":"10.1111\/eci.13013","article-title":"Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings","volume":"48","author":"Iannone","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0038","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-Findings from a United Kingdom cohort","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology (United Kingdom)"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152078_bib0039","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3899\/jrheum.17666","article-title":"The sex influence on response to tumor necrosis factor-alpha inhibitors and remission in axial spondyloarthritis","volume":"45","author":"Lubrano","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152078_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105358","article-title":"Factors associated with drug-free remission at 5 year in early onset axial spondyloarthritis patients: data from the DESIR cohort","author":"Ruyssen-Witrand","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152078_bib0041","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","article-title":"Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152078_bib0042","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152078_bib0043","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:04Z","timestamp":1758733924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":43,"alternative-id":["S0049017222001299"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152078","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of remission in people with axial spondyloarthritis: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152078"}}